1. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral- naïve HIVinfected adults. AIDS 20:2051-64. 2006.
  2. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358:2095-106. 2008.
  3. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (米国DHHS、October 25, 2018). https://www.aidsinfo.nih.gov/よりダウンロード可能
  4. The European Guidelines for Treatment of HIV Infected Adults in Europe (European AIDS Clinical Society, version 9.1 - October 2018). http://www.europeanaidsclinicalsociety.org/よりダウンロード可能
  5. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults:2018 Recommendations of the international antiretroviral society-USA panel. JAMA. 320: 379-96. 2018.
  6. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune
    Defic Syndr. 63(1):77-85.2013.
  7. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161(7):461-471.2014.
  8. Cahn P, Kaplan R, Sax PE, et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, noninferiority trial. Lancet HIV. 4: e486-e494. 2017.
  9. Cahn P, Sax PE, Squires K, et al. Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, non-inferiority trial. J Acquir Immune Defic Syndr.78(5): 589-98. 2018.
  10. Zolopa A, Sax PE, DeJesus E, et al. A randomized doubleblind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysisof week 96 results. J Acquir Immune Defic Syndr. 63:96-100. 2013.
  11. Rockstroh JK, DeJesus E, Henry K, et al. A randomized, doubleblind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 62:483-86. 2013.
  12. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 385: 2606-15.2015.
  13. Wohl D, Oka S, Climeck N, et al. Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr.72:58-64.2016.
  14. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis.16: 43-52.2016.
  15. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis.13:927-35.2013.
  16. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection. N Engl J Med.369:1807-18. 2013.
  17. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 383: 2222- 31.2014.
  18. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, doubleblind, multicentre, phase 3, non-inferiority trial. Lancet. 390: 2073-82.2017.
  19. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 390: 2063-72.2017.
  20. Wohl D, Yazdanpanah Y, Baumgarten A, et al. A phase 3, randomized, controlled clinical trial of bictegravir in a fixed-dose combination, B/F/TAF, vs DTG/ABC/3TC in treatment-naïve adults at week 96. San Francisco: IDWeek; 2018.
  21. Stellbrink HJ, Arribas J, Stephens JL, et al. Phase III randomized, controlled clinical trial of bictegravir coformulated with ftc/taf in a fixed-dose combination (B/F/ATF) versus dolutegravir (DTG) + F/TAF in treatment-naïve hiv-1 positive adults: week 96. HIV Drug Ther. Glasgow, UK; 2018.
  22. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1- infected patients: 96-week analysis. AIDS 23:1679-88. 2009.
  23. Tashima K, Crofoot G, Tomaka F, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Research and Therapy; 11:39.2014.
  24. Echeverría P, Bonjoch A, Puig J, et al. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med.18(10):782-786.2017.
  25. Cohen C, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet; 378: 229-237.2011
  26. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet; 378: 238-246.2011
  27. Sax PE, Tierney C, Collier AC, et al. Abacavirlamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361:2230-40. 2009.
  28. Daar E, Tierney C, Fischl, M, et al. ACTG 5202: Final Results of ABC/3TC or TDF/FTC with either EFV or ATV/r in Treatment- naïve HIV-infected Patients. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. February 16-19, 2010. Abstract 59LB.
  29. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23:1547-56. 2009.
  30. Post F, Moyle G, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and sefety with once-daily Abcavir/Lamivudine versus Tenofovir/ Emtricitabine, administered with Efavirenz, in antiretroviral- naïve, HIV-1infected adults: 48-week results from ASSERT study. JIADS 55 49-57. 2010.
  31. Nishijima T, Komatsu H, Teruya K, et al. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricita-bine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml. AIDS.27:839-48.2013
  32. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 371:1417-26. 2008.
  33. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 201:318-30. 2010.
  34. Ding X, Andraca-Carrera E, Cooper C, et al. No Association of Abacavir Use with Myocardial Infarction:Findings of an FDA Metaanalysis. J Acquir Immune Defic Syndr.61:441-7. 2012.
  35. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5:203-11. 2004.
  36. Tanaka H, Akaza T, Juji T. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl:139-44. 1996.
  37. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavirritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368:476-82. 2006.
  38. Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 60:599-604. 2007.
  39. Mallal S. Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-32. 2002.
  40. Yoshino M, Nagai S, Kuwahara T, et al. The clinical experience of abacavir in HIV-infected Japanese. 7th International Congress on AIDS in Asia, abstract # MoPB0088.
  41. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36:1070-3. 2003.
  42. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 42:283-90. 2006.
  43. Gallant JE, and Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23:1971-5. 2009.
  44. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naïve patients. J Acquir Immune Defic Syndr 53:62-9. 2010.
  45. Kinai E, and Hanabusa H. Progressive renal tubular dysfunction associated with longterm use of tenofovir DF. AIDS Res Hum Retroviruses 25:387-94. 2009.
  46. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIVinfected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6(7):e22661.
  47. Arribas JR, Thompson M, Sax PE, et al. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr.75(2):211-8. 2017.
  48. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. (米国DHHS、December 7, 2018). https://www.aidsinfo.nih.gov/よりダウンロード可能
  49. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents (米国DHHS, updated November 29, 2018). https://www.aidsinfo.nih.gov/よりダウンロード可能
  50. Mollan KR, Smurzynski M, Eron JJ, et al. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide. Ann Intern Med.161:1-10.2014.
  51. Hamada Y, Nishijima T, Watanabe K, et al. High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. Clin Infect Dis. 55(9):1262-19, 2012.
  52. Cahn P, Madero JS, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection 48-week results from the GEMINI studies. Presented at: 22nd International AIDS Conference (AIDS 2018). Amsterdam, Netherlands. 2018.
  53. Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised noninferiority trial. Lancet. 384(9958):1942-51.2014.
  54. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatmentnaïve HIV-1-infected patients (ACTG A5262). AIDS. 25(17):2113-2122. 2011
  55. Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviralnaive patients. Impact on bone health. PloS one. 9(8):e106221. 2014.
  56. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-na?ve subjects with CCR5-tropic HIV-1 infection. J Infect Dis.201:803-13. 2010.
  57. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133:21-30. 2000.
  58. Graeme Moyle. The APPT-1 study: assessing patients’ preferred treatments. Sixth International Congress on Drug Therapy in HIV Infection (2002). Abstract #9
  59. Vrijens B, Comte L, Tousset E, Urquhart J. Once-daily versus twice-daily regimens: which is best for HIV infected patients? The 6th International Workshop on Clinical Pharmacology of HIV Therapy. Abstract #3, 2005.
  60. Glass TR, Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV Cohort Study. JAIDS 41: 385-92, 2006.
  61. Carrieri M, Leport C, Protopopescu C, et al. Factors associated with nonadherence to highly active antiretroviral therapy: A 5- year follow-up analysis with correction for the bias induced by missing data in the reatment maintenance phase. JAIDS 41: 477- 2006.
  62. Murri R, Marcotullio S, Lupoli P, et al. Is "once-daily" regimen a key strategy for improving adherence to antiretroviral regimens? J Acquir Immune Defic Syndr 42:259-60. 2006.
  63. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis 58(9):1297-1307.2014.
  64. Vrijens B, Tousset E, Rode R, et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data
  65. HIV診療における外来チーム医療マニュアル改訂第2版(厚生労働行政推進調査事業費補助金(エイズ対策政策研究事業)「HIV感染症及びその合併症の課題を克服する研究」班):https://www.haart-support.jp/manual/index.htm
  66. 日笠 聡、小島賢一、増田純一、関根祐介.抗HIV療法と服薬援助のための基礎的調査–治療開始時の抗HIV 薬処方動向調査(2018年)–2018年第32回日本エイズ学会学術集会・総会(大阪)、抄録番号O9-043
  67. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 391:839-49. 2018.